Recent advances and controversies in surgical management of hepatocellular carcinoma of hepatocellular carcinoma.
- Author:
Jia-mei YANG
1
Author Information
1. Department of Special Service and Liver Transplantation, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China. yangjiamei@smmu.edu.cn
- Publication Type:Journal Article
- MeSH:
Carcinoma, Hepatocellular;
pathology;
surgery;
Humans;
Intraoperative Complications;
prevention & control;
Liver Neoplasms;
pathology;
surgery;
Liver Transplantation;
Randomized Controlled Trials as Topic
- From:
Acta Academiae Medicinae Sinicae
2008;30(4):378-380
- CountryChina
- Language:Chinese
-
Abstract:
Surgical treatment of hepatocellular carcinoma (HCC) has made great progress in recent ten years, although the appropriate selection of treatment methods remains controversial. Surgical resection of HCC is still widely recognized as the first choice, which has been remarkably improved by effectively controlling intra-operative bleeding. However, the ischemia/reperfusion injury and long-term recurrence still proposes challenges to Pringle's maneuver. The indications of liver transplantation also expand in recent years, and many centers have used marginal donor liver and living donor liver. Remission of the shortage of donors, local ablation of small HCC, and surgical resection still lack the support of randomized controlled trials. In summary, the surgical treatment of HCC should strictly based on the indications of various therapies, which should be prudently verified by randomized controlled trials.
